Table 3.
NVP-CGM097 did not affect ABCG2-mediated MDR.
| Treatment | IC50 ± SDa (RFb)(μM) | |
|---|---|---|
| NCI-H460 | NCI-H460/MX20 | |
| Mitoxantrone | 0.035 ± 0.002 (1.00) | 5.567 ± 0.011 (159.05) |
| +NVP CGM097 (1 μM) | 0.029 ± 0.001 (0.82) | 5.762 ± 0.177 (164.63) |
| +NVP CGM097 (3 μM) | 0.026 ± 0.023 (0.74) | 5.538 ± 0.039 (158.23) |
| +Ko143(3 μM) | 0.025 ± 0.002 (0.71) | 0.404 ± 0.005 (11.54)* |
| Cisplatin | 2.871 ± 0.012 (1.00) | 2.698 ± 0.333 (0.94) |
| +NVP CGM097 (1 μM) | 2.602 ± 0.074 (0.91) | 2.346 ± 0.174 (0.82) |
| +NVP CGM097 (3 μM) | 2.611 ± 0.05 (0.91) | 3.101 ± 0.039 (1.08) |
| +KO143 (3 μM) | 2.903 ± 0.063 (1.01) | 2.212 ± 0.313 (0.77) |
a
IC50 values were determined by MTT assay as described in “Materials and Methods,” and were obtained from three independent experiments in triplicate.
b
Resistance fold (RF) was calculated from dividing the IC50 values of resistant cells (NCI-H460/MX20) by the IC50 of parental cells (NCI-H460) in the presence or absence of NVP-CGM097 or positive control inhibitor.
*
p < 0.05 vs. group treated with antineoplastic drug only.